4//SEC Filing
Merck KGaA 4
Accession 0001104659-21-130030
CIK 0001840233other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 5:06 PM ET
Size
12.2 KB
Accession
0001104659-21-130030
Insider Transaction Report
Form 4
Merck KGaA
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2021-10-26−3,952,568→ 0 total(indirect: See Footnote)→ Common Stock (416,060 underlying) - Conversion
Series C Preferred Srock
2021-10-26−2,515,271→ 0 total(indirect: See Footnote)→ Common Stock (264,765 underlying) - Conversion
Common Stock
2021-10-26+416,060→ 416,060 total(indirect: See Footnote) - Conversion
Common Stock
2021-10-26+264,765→ 680,825 total(indirect: See Footnote)
Footnotes (3)
- [F1]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
- [F2]The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
- [F3]The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
IncorporatedGermany
Related Parties
1- filerCIK 0001764133
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 5:06 PM ET
- Size
- 12.2 KB